Novel plasma protein binding analysis method for a PET tracer and its radiometabolites: A case study with [11C]SMW139 to explain the high uptake of radiometabolites in mouse brain

Article

Author: Haaparanta-Solin, Merja ; Forsback, Sarita ; Aarnio, Richard ; Wahlroos, Saara ; Alzghool, Obada M ; O'Brien-Brown, James ; Rinne, Juha O ; Solin, Olof ; Kassiou, Michael

Radiometabolites of PET tracers interfere with imaging and need to be taken into account when modeling PET data. Various tracer and radiometabolite characteristics affect the uptake rate into tissue. In this study, we investigated two such factors, lipophilicity and protein-free fraction. A novel rapid method was developed using thin-layer chromatography with digital autoradiography (radioTLC) and ultrafiltration for analyzing the protein-free fractions of an exemplar PET tracer, [¹¹C]SMW139 (f_P, free parent tracer over all radioactivity), and its radiometabolites (f_M, free radiometabolites over all radioactivity). Detailed understanding of the uptake of radiometabolites into extravascular cells requires analyzing f_M, which has not previously been performed for PET tracers. Mice were injected with [¹¹C]SMW139, and time-activity curves from plasma and brain coupled with the parent fraction and free fraction data were analyzed to demonstrate the true levels of protein-free and protein-bound [¹¹C]SMW139 and its radiometabolites in plasma. The ultrafiltration method included separate membrane correction factors for the parent tracer and its radiometabolites for analysis of unbiased f_P and f_M. Metabolism of [¹¹C]SMW139 was rapid, and after 45 min, the parent fraction was 0.33 in plasma and 0.28 in brain. Ultrafiltration membrane correction had a significant effect on the f_P but not the f_M. From 10-45 min, the f_P decreased from 0.032 to 0.007, while f_M remained between 0.52 and 0.35. The much higher f_M in plasma could explain why the less lipophilic radiometabolites enter the brain efficiently. This detailed understanding of f_P and f_M from rodents can be used in translational studies to explain the behavior of the tracer in humans. Similar parent fraction and plasma protein binding methods can be used for human in vivo analysis.

01 Feb 2020·TalantaQ2 · CHEMISTRY

New approach in radiometabolite analysis of positron emission tomography (PET) radioligands; lead-shielded microextraction by packed sorbent as a tool for in vivo radiometabolite analysis of [11C]SMW139 in rat plasma

Q2 · CHEMISTRY

Article

Author: Abdel-Rehim, Mohamed ; Moein, Mohammad Mahdi ; Varrone, Andrea ; Tóth, Miklós ; Halldin, Christer ; Tari, Lenke

The blood plasma radiometabolite analysis (RMA) is crucial procedure for quantitative analysis of positron emission tomography (PET) radioligands with no original reference region in the brain. Blood sampling and separating plasma for RMA has been a challenge especially with small animal PET research. This work aimed to overcome this problem by presenting a semi-automated lead shielded microextraction by packed sorbents (SLS-MEPS). The capability of SLS-MEPS was evaluated for RMA of [¹¹C]SMW139 as a PET radioligand in rat plasma samples. [¹¹C]SMW139 is a potential radioligand with high receptor binding for P2X₇R in vivo. The validation method was individually performed for [¹¹C]SMW139 and [¹²C]SMW139 with reversed phase high performance liquid chromatography (HPLC) utilizing radio- and UV-detector, respectively. The limits of detection (LOD) and quantification (LOQ) [¹¹C]SMW139 in rat plasma were 3 and 10 Becquerel (Bq), respectively. The standard calibration curve was obtained for [¹¹C]SMW139 within the concentration range 10-15000 Bq with over 0.995 coefficients for all assays. In addition, the capability of SLS-MEPS in combination with HPLC-UV for extraction of [¹²C]SMW139 in rat plasma was also challenged and the obtained results showed a proper linearity (20-2000 μg mL^-1), accuracy and repeatability.

100 Deals associated with 11C-SMW-139

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Neurodegenerative Diseases	Preclinical	AU	The University of Sydney	-
Neurodegenerative Diseases	Preclinical	BE	Leuven innovatie VZW	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

11C-SMW-139

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation